

LEADERSHIP TEAM

Stephen Van Deventer
Chairman, CEO & President (Canada)
Chairman & Director (Australia)

Mak Jawadekar, PhD
Chief Science Officer & Director (Canada)

Greg Reid
Director (Canada)

Matt Coltura
Director (Canada)

Shabira Rajan, MBA, CPA, CGA
Chief Financial Officer & Controller (Canada)
Chief Financial Officer (Australia)

Harry Parekh, PhD, BSc Honst
Chief Research Officer (Canada)

Maher Khaled PhD, LLB, BSc
Director of International Operations (Canada)
CEO & Corp Secretary (Australia)

PreveCeutical Medical Inc., (CSE: PREV, OTCQB: PRVCF) is a health and wellness company, focused on developing nature identical products for the benefit of health-conscious consumers.

The company was founded by Mr. Stephen Van Deventer and Ms. Kimberly Van Deventer who are passionate about health and well being.

Mission Statement

To improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products.

Vision

To be a trusted leader in providing preventive and therapeutic health solutions that contribute to lasting health and well-being.

RESEARCH AND DEVELOPMENT PROGRAMS



SOL-GEL DELIVERY PLATFORM

- Formulation of CBD infused soluble-gels
- Analysis of plant-derived CBDs provided by Aurora Cannabis Inc.
- Perform delivery studies




PEPTIDE RESEARCH PROGRAM

- Identification of peptides
- Synthesis and stabilization




DUAL GENE THERAPY

- Tissue targeted, bio-responsive gene delivery systems
- Systematic evaluation towards gene and protein silencing in appropriate models – *multiple phases curative therapy for type 2 diabetes & obesity*



PEPTIDE THERAPEUTICS (PAIN RELIEF)

- Developing non-addictive analgesic peptides aiming to relieve moderate to severe pain.



Research and Development Programs Timeline

RESEARCH AND DEVELOPMENT PROGRAMS



Our research and development programs are with UniQuest, the main commercialisation company of the University of Queensland. The programs are led by Dr. Harendra Parekh, Preveceutical's Chief Research Officer and a UQ researcher. All intellectual property developed during the programs will be owned by Preveceutical.

Sol-Gel CBD Delivery Platform Using Aurora Cannabis Inc.'s Dried Cannabis Flower and Oils

Developing what we believe to be the first, sustained release, CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Sol-gels are taken via nasal (systemic) administration and rapidly gel upon contact with mucosal tissue.

Key advantages of our proprietary formulations:

- Eliminates first pass metabolism (stomach, intestines, liver) – potentially improving bioavailability
- Extended time release, up to seven days – alleviating side effects of high dosage therapeutics and reducing symptoms
- *Universally-patient friendly, safe for children and adults*

Venom Re-engineering (Peptide Research Program)

Currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where an unmet clinical need exists, such as cancer. There are numerous research papers in the public domain which show anecdotal findings and efficacy of venom peptides.

Our initial focus:

- Targeting glioma, an aggressive form of brain cancer
- Screen our library of nature identical peptides across a range of other cancers

Dual Gene Therapy

**Collaborators: QIMR Berghofer – Professor Grant Ramm and Murdoch University – Dr Rakesh Veedu.*

This program paves the way for preclinical evaluation of proprietary chemistry that targets the gene implicated in both type 2 diabetes and obesity. Reducing the capacity to store fat can reverse obesity and fatty liver disease, alleviating the condition rather than just managing it.

Involves:

- Four year research program, starting mid-2018
- Therapeutic strategy evolved from over five years of multi-disciplinary research

Engineering Peptide Therapeutics for Non-Addictive Analgesia

Signed a R&D option agreement proposing to develop peptides, incorporating UQ's disulfide linker technology, as non-addictive analgesics (pain relief) for moderate-to-severe pain

Involves:

- Peptide library synthesis
- Pharmacological evaluation
- Pharmacokinetic assessment and efficacy determinations

Joint Venture

Joint Venture with Sports 1 Marketing to develop a therapy geared towards athletes who suffer from concussions (Mild Traumatic Brain Injury).

Next Steps

International Licensing Agreements/Further Research and Development Projects/Growth Potential

DISCLAIMER

This fact sheet ("Fact Sheet") has been prepared by PreveCeutical Medical Inc. ("PreveCeutical" or the "Company") (CSE: PREV) (FSE: 18H). This Fact Sheet contains certain forward-looking statements relating to the potential business, financial performance and results of the Company and/or industries and markets in which it is or may operate within, including forward-looking forecasts. These statements may contain words such as "will", "expects", "anticipates", "believes", "estimates" and words of similar import. Any forward-looking statements and other information contained in this Fact Sheet, including assumptions, opinions, forecasts and views, including those cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. As such by the nature of any forward-looking statement, relying on such statements involves risk. This Fact Sheet may contain information which has been sourced from third parties believed to be reliable, but without independent verification by the Company. Its board of directors, management, employees, consultants, agents, or affiliates. This Fact Sheet is prepared for discussion and informational purposes only, and does not constitute, and should not be construed as, any general advertisement, general solicitation, offer, invitation, solicitation, or recommendation to buy or sell any of the securities issued by the Company in any jurisdiction, and does and will not constitute or form or be part of any offering material. Such an offer can only be made by prospectus, registration statement, other authorized offering document, or in reliance on an exemption to such requirement(s). This Fact Sheet is not meant for and should not be distributed to U.S. Persons (as defined in Regulation S of the United States Securities Act of 1933, as amended) or otherwise distributed in the United States of America. This Fact Sheet has not been reviewed or registered with any public authority, securities commission, stock exchange, or regulated market place. You (the reader) are solely responsible for your own assessment of the information contained in this Fact Sheet. This Fact Sheet may be subject to corrections and change at any time without notice. Neither the Company nor any subsidiary of the Company or any such person's board of directors, management, employees, consultants, agents, or affiliates intends to, and neither the delivery of this Fact Sheet nor any further discussions with any recipient shall, under any circumstances, create any implication that the Company or any of the aforementioned parties assumes any obligation to update or correct the information herein unless required by applicable law. The information in this Fact Sheet is current as of the date of this Fact Sheet noted on its first page or the date of publication (as applicable), and readers are encouraged to review the Company's public filings on its SEDAR profile on www.sedar.com.

CONTACT

Deanna Kress
Director of Corporate
Communications & Investor Relations
Cell: 1(778) 999-6063
Office: 1(604) 416-7777 ext.6288
deanna@preveceutical.com